InMed Pharmaceuticals Inc. (FRA:MWG)
Germany · Delayed Price · Currency is EUR 1.090
-0.020 (-1.80%)
At close: Nov 28, 2025
InMed Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| 4.8 | 4.94 | 4.6 | 4.14 | 1.09 | - | Upgrade | |
Revenue Growth (YoY) | -3.27% | 7.50% | 11.18% | 279.61% | - | - | Upgrade |
Cost of Revenue | 3.18 | 3.24 | 3.5 | 2.73 | 0.55 | - | Upgrade |
Gross Profit | 1.62 | 1.71 | 1.1 | 1.4 | 0.54 | - | Upgrade |
Selling, General & Admin | 6.6 | 6.56 | 5.8 | 5.85 | 6.67 | 4.48 | Upgrade |
Research & Development | 2.74 | 2.85 | 3.22 | 3.73 | 7.28 | 5.34 | Upgrade |
Operating Expenses | 9.54 | 9.62 | 9.24 | 9.78 | 14.14 | 9.94 | Upgrade |
Operating Income | -7.93 | -7.92 | -8.13 | -8.38 | -13.59 | -9.94 | Upgrade |
Interest & Investment Income | 0.19 | 0.16 | 0.53 | 0.49 | 0.1 | 0.02 | Upgrade |
Currency Exchange Gain (Loss) | -0.1 | -0.03 | -0.06 | -0.05 | -0.12 | -0.16 | Upgrade |
Other Non Operating Income (Expenses) | -0.37 | -0.37 | - | - | - | -0.12 | Upgrade |
EBT Excluding Unusual Items | -8.21 | -8.16 | -7.67 | -7.93 | -13.61 | -10.2 | Upgrade |
Merger & Restructuring Charges | - | - | - | - | -0.2 | - | Upgrade |
Impairment of Goodwill | - | - | - | - | -2.02 | - | Upgrade |
Asset Writedown | - | - | - | - | -1.45 | - | Upgrade |
Other Unusual Items | - | - | - | - | -1.31 | - | Upgrade |
Pretax Income | -8.21 | -8.16 | -7.67 | -7.93 | -18.6 | -10.2 | Upgrade |
Income Tax Expense | - | - | 0.01 | 0.01 | - | - | Upgrade |
Net Income | -8.21 | -8.16 | -7.68 | -7.95 | -18.6 | -10.2 | Upgrade |
Net Income to Common | -8.21 | -8.16 | -7.68 | -7.95 | -18.6 | -10.2 | Upgrade |
Shares Outstanding (Basic) | 4 | 1 | 0 | 0 | 0 | 0 | Upgrade |
Shares Outstanding (Diluted) | 4 | 1 | 0 | 0 | 0 | 0 | Upgrade |
Shares Change (YoY) | 699.74% | 156.13% | 211.26% | 336.59% | 108.64% | 28.72% | Upgrade |
EPS (Basic) | -2.08 | -8.36 | -20.14 | -64.92 | -663.32 | -759.16 | Upgrade |
EPS (Diluted) | -2.08 | -8.36 | -20.14 | -64.92 | -663.32 | -759.16 | Upgrade |
Free Cash Flow | -7.55 | -7.77 | -7 | -7.45 | -15.62 | -9.79 | Upgrade |
Free Cash Flow Per Share | -1.91 | -7.96 | -18.36 | -60.81 | -557.14 | -728.60 | Upgrade |
Gross Margin | 33.69% | 34.53% | 23.95% | 33.93% | 49.89% | - | Upgrade |
Operating Margin | -165.22% | -160.20% | -176.92% | -202.60% | -1247.60% | - | Upgrade |
Profit Margin | -171.13% | -165.14% | -166.94% | -192.18% | -1707.32% | - | Upgrade |
Free Cash Flow Margin | -157.31% | -157.14% | -152.14% | -180.02% | -1434.03% | - | Upgrade |
EBITDA | -7.72 | -7.71 | -7.91 | -8.18 | -13.41 | -9.82 | Upgrade |
EBITDA Margin | -160.81% | -155.89% | -172.15% | -197.71% | - | - | Upgrade |
D&A For EBITDA | 0.21 | 0.21 | 0.22 | 0.2 | 0.19 | 0.12 | Upgrade |
EBIT | -7.93 | -7.92 | -8.13 | -8.38 | -13.59 | -9.94 | Upgrade |
EBIT Margin | -165.22% | -160.20% | -176.92% | -202.60% | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.